community c diff infections

potentially useful study done in Denmark looking at the prevalence of c. difficile infections in community patients seen for unformed stools (see cdiff in community clin microbio 2014​ in dropbox, or doi.org/10.1111/1469-0691.12758#sthash.lfaoG3fB.dpuf). details:

--12174 "unformed stool" samples sent to lab for evaluation for any enteric pathogen by general practitioners were then automatically tested for c. diff
--194 samples (1.5%) were positive for c diff, comparable to incidence of salmonella. they did nested case-control study, with 152 c diff patients compared with 304 age and sex-matched controls and using weighted multi-variable logistic regression
--compared to others with diarrhea, those with c diff had more severe complaints, underlying diseases, antibiotic use, prior hospitalization (none of this particularly surprising)
--but in Denmark, MDs requested c diff testing in only 7% of samples (which detected only 40% of the cases)
--and, if following the Danish recommendations that c diff be checked if patient had prior antibiotic use or hospitalization, only 61% of cases would have been detected.

so, this study confirms some others that found that over 1/3 of community-based c diff infections have no known risk factors!! this study brings up a couple of important issues (assuming the community prevalence of c diff is similar here as in denmark -- a study in the UK for example did not find much c diff in the community):
--c diff prevalence is similar to other enteric pathogens that we test for.  so, we should consider testing for c diff whenever we decide it is appropriate to test for the other pathogens
--c diff offers particular issues which highlight the utility of diagnosing it: recurrence is frequent -- in this study in which 80% of the c diff positive patients had followup, 79% of them received treatment (mostly metronidazole), and 25% had recurrent diarrhea within 6 months with confirmed c diff positive in 37% of them. and 4% were hospitalized, 1% had c diff as contributing cause of death (they did not note whether treatment altered the recurrence rate). by the way, the issue of recurrence in c diff infection is pretty complex and is typically cited in the 25% range. in some studies about 1/2 of recurrent infections are actually reinfection with different c diff strain and not true recurrence. also, the use of antibiotics (metronidazole and/or vanco) alter the gut microbiome dramatically and potentially increase the likelihood of recurrence, esp if a few c diff spores evade the antibiotics, as well as reinfection (which raises question of utility of probiotics???)

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

cystatin c: better predictor of bad outcomes than creatinine

  another article found significant discordance between creatinine and cystatin C in assessing renal function,  finding that the latter correlated most strongly with both renal and non-renal adverse clinical outcomes (see   ckd cystatin c better than creat AJKD2023  in  dropbox or doi: 10.1053/ j.ajkd.2023.04.002)   Details: -- 158,601 adults who were in the Stockholm Creatinine Measurements (SCREAM) project and had testing of creatinine and cystatin C on the same day during a healthcare encounter, from 2010-2018     -- >400,000 outpatient tests were done for both creatinine and cystatin C levels -- mean age 62, 48% female -- mean eGFR by creatinine (   eGFR cr ) 80; mean eGFR by cystatin C ( eGFR cys  ) 73 -- mean stage of renal insufficiency: 39%  eGFR cr   90+; 38%  eGFR cr  60-89; 12%  eGFR cr  45-59; 7.1%  eGFR cr  30-44; 3.2%  eGFR cr  15-29, 0.7%  eGFR cr ...
Read more

diabetes DPP-4 inhibitors and the risk of heart failure

the FDA just came out with a safety alert about 2 DPP-4 inhibitors and the increased risk of heart failure (released 04/05/2016)(see  http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery ​ ). details: --saxagliptin and alogliptin were singled out because of 2 clinical trials in diabetic patients with heart disease. in each trial more patients taking these meds were hospitalized for heart failure vs those on placebo     --in the saxagliptin trial: 3.5% were hospitalized for heart failure (vs 2.8% on placebo). risk factors included prior heart failure or kidney disease     --in the alogliptin trial: 3.9% were hospitalized for heart failure (vs 3.3% on placebo) --recommendation by the FDA:     -- we should consider stopping these drugs if the patient develops heart failure ...
Read more

UPDATE: ASCVD risk factor critique

I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the current ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:          ...
Read more